Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.43 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.39 |
| ▸ | P2RY10 | O00398 | 9/20 | 0.38 |
| ▸ | GPR34 | Q9UPC5 | 5/20 | 0.38 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144721 | 1.00 | PLA2G2C (0.43) | PLA2G2CPLA2G2DP2RY10GPR34LPAR6 | |
| SCHEMBL19410782 | 1.00 | PLA2G2C (0.43) | PLA2G2CPLA2G2DP2RY10GPR34LPAR6 | |
| SCHEMBL37519 | 1.00 | PLA2G2C (0.43) | PLA2G2CPLA2G2DP2RY10GPR34LPAR6 | |
| SCHEMBL226745 | 1.00 | PLA2G2C (0.43) | PLA2G2CPLA2G2DP2RY10GPR34LPAR6 | |
| SCHEMBL18262003 | 0.94 | P2RY10 (0.44) | P2RY10GPR34LPAR6LPAR1LPAR4 | |
| SCHEMBL969822 | 0.94 | P2RY10 (0.44) | P2RY10GPR34LPAR6LPAR1LPAR4 | |
| SCHEMBL7571747 | 0.94 | P2RY10 (0.44) | P2RY10GPR34LPAR6LPAR1LPAR4 | |
| SCHEMBL7570925 | 0.91 | S1PR1 (0.47) | P2RY10GPR34 | |
| SCHEMBL7203823 | 0.91 | PLA2G2C (0.36) | PLA2G2CPLA2G2D | |
| SCHEMBL5312425 | 0.87 | ALDH1A1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252678-A1 | SYNTHETIC EXOSOMES (SE) FOR CNS DELIVERY OF CRISPR FOR GENE EDITING IN BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-01 | — | — | US | claimed |
| EP-4401782-A1 | SYNTHETIC EXOSOMES (SE) FOR CNS DELIVERY OF CRISPR FOR GENE EDITING IN BRAIN DISORDERS | The Regents of University of California (US) | 2024-07-24 | — | — | EP | claimed |
| US-20230285291-A1 | MANUFACTURING OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-14 | — | — | US | claimed |
| WO-2023043700-A1 | SYNTHETIC EXOSOMES (SE) FOR CNS DELIVERY OF CRISPR FOR GENE EDITING IN BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-23 | — | — | WO | claimed |
| EP-4132584-A1 | MANUFACTURING OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-15 | — | — | EP | claimed |
| EP-4676942-A1 | PROTAMINE MOLECULES AND USES THEREOF | The University of British Columbia (CA) | 2026-01-14 | — | — | EP | disclosed |
| US-12233131-B2 | Cationic calibrated-size gas-filled microvesicles | BRACCO SUISSE SA (CH) | 2025-02-25 | — | — | US | disclosed |
| WO-2024184779-A1 | PROTAMINE MOLECULES AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-09-12 | — | — | WO | disclosed |
| US-20240277866-A1 | CATIONIC CALIBRATED-SIZE GAS-FILLED MICROVESICLES | BRACCO SUISSE SA (CH) | 2024-08-22 | — | — | US | disclosed |
| US-20240252678-A1 | SYNTHETIC EXOSOMES (SE) FOR CNS DELIVERY OF CRISPR FOR GENE EDITING IN BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-01 | — | — | US | disclosed |
| EP-4401782-A1 | SYNTHETIC EXOSOMES (SE) FOR CNS DELIVERY OF CRISPR FOR GENE EDITING IN BRAIN DISORDERS | The Regents of University of California (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4370162-A1 | CATIONIC CALIBRATED-SIZE GAS-FILLED MICROVESICLES | Bracco Suisse SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| US-20230285291-A1 | MANUFACTURING OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2023043700-A1 | SYNTHETIC EXOSOMES (SE) FOR CNS DELIVERY OF CRISPR FOR GENE EDITING IN BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-23 | — | — | WO | disclosed |
| EP-4132584-A1 | MANUFACTURING OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2023285628-A1 | CATIONIC CALIBRATED-SIZE GAS-FILLED MICROVESICLES | BRACCO SUISSE SA (CH) | 2023-01-19 | — | — | WO | disclosed |
| WO-2009129387-A2 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277866-A1 | CATIONIC CALIBRATED-SIZE GAS-FILLED MICROVESICLES | GSDMD, CHMP4B, SGMS2 | PLA2G2C 173/4885PLA2G2D 11/4885P2RY10 1656/4885 |
| US-12233131-B2 | Cationic calibrated-size gas-filled microvesicles | GSDMD, CHMP4B, SGMS2 | PLA2G2C 185/4885PLA2G2D 18/4885P2RY10 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.